Senolytic drugs: from discovery to translation
Kirkland JL, Tchkonia T
Published in Journal of Internal Medicine
Methodology
Narrative review of senolytic drug discovery, mechanisms and early human translation, covering dasatinib, quercetin, fisetin and navitoclax
Key Findings
Senolytics transiently disable senescent-cell anti-apoptotic pathways and delay or alleviate multiple age-related disorders in preclinical models; human evidence remains early stage.
Conclusions
Senolytics are a promising but still translational class; clinical benefit in humans is not yet established.
Limitations
Narrative review rather than systematic; heavy reliance on animal data; author conflicts in senolytic development.
Supplements Studied
Outcomes Measured
Senolytics transiently disable these SCAPs, causing apoptosis of those SC with a tissue-destructive SASP.
Study Details
Access Study
Disclosures
Funding
NIH extramural
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.